Mesa Laboratories, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Siddhartha C. Kadia
- Full Time Employees
- 717
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- 12100 West Sixth Avenue Lakewood CO United States of America 80228
- IPO Date
- Feb 29, 1984
- CIK
- 0000724004
- Website
- mesalabs.com
- Similar Companies
- Business
- Mesa Laboratories, Inc. is a global leader in the design, manufacture, and marketing of life science tools and critical quality control solutions for regulated applications primarily in the pharmaceutical, healthcare, and medical device industries. The company offers a broad range of core products including biological and chemical indicators for sterilization monitoring; high-performance data loggers and continuous monitoring systems for temperature, humidity, pressure, and environmental conditions; torque analyzers for cap and container testing; renal care quality control devices such as advanced digital dialysate meters; and air and gas flow measurement instruments. Mesa’s product portfolio serves diverse end markets encompassing pharmaceutical manufacturing, healthcare facilities, medical device production, and industrial applications, supporting product integrity, patient safety, and regulatory compliance. Founded in 1983 and headquartered in Lakewood, Colorado, Mesa Laboratories operates globally with recent notable expansions in both geographic reach and product offerings. A key recent development is the acquisition and integration of GKE Science & Technology Co., including its sterilization indicators business and independent testing lab, completed at the end of 2023. This strategic acquisition has expanded Mesa’s presence in China and Europe and is expected to contribute significant revenue growth. Mesa also executed a financial strategy in 2025 involving the repayment of $97.5 million of convertible senior notes and drew additional funds under its credit facility to optimize capital structure and support long-term growth initiatives while reducing potential shareholder dilution. In addition to acquisitions, Mesa has undertaken restructuring efforts in its Clinical Genomics division to align costs with evolving revenue dynamics and improved procurement processes, resulting in inventory reductions and enhanced supply chain management. The company maintains a strong focus on continuous innovation and compliance, offering products certified to ISO and FDA standards to meet stringent regulatory requirements globally. Mesa Laboratories continues to invest in research and development to enhance its life science tools and quality control solutions, positioning itself as a trusted partner to multinational pharmaceutical companies, healthcare providers, and medical device manufacturers worldwide.
Company News
Mesa Laboratories Inc (MLAB) Shares Surge 4.1% -- What GF Score of 75 Tells Investors
Reviewing ImmunoPrecise Antibodies (OTCMKTS:IPATF) & Mesa Laboratories (NASDAQ:MLAB)
Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript
Mesa Laboratories Q1 Earnings Call Highlights
Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call
MESA LABS DECLARES QUARTERLY DIVIDEND
Why Mesa Laboratories Stock Is Getting Hit With a Huge Sell-Off Today
Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results
Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories (NASDAQ:MLAB) Stock Price Passes Above 200-Day Moving Average – Here’s What Happened
Royce Small-Cap Fund FY 2025: What Worked
Principal Financial Group Inc. Decreases Stock Holdings in Mesa Laboratories, Inc. $MLAB
Mesa Laboratories, Inc. $MLAB Shares Bought by Diamond Hill Capital Management Inc.
Mesa Laboratories (MLAB) to Release Quarterly Earnings on Tuesday
Mesa Laboratories, Inc. (MLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Financial Review: Accuray (NASDAQ:ARAY) & Mesa Laboratories (NASDAQ:MLAB)
Mesa Laboratories, Inc. to Participate in Upcoming Investor Conferences